【警告】 strong>
Lotensin HCT禁用于无尿患者。
对于对苯那普利,任何其他ACE抑制剂,氢氯噻嗪或其他磺胺衍生药物过敏的患者,Lotensin HCT也是禁忌的。 有过敏史或支气管哮喘病史的患者更容易发生过敏反应。
对于有或没有ACE抑制剂治疗的血管性水肿史患者,Lotensin HCT也是禁忌的。
Lotensin HCT与脑啡肽酶抑制剂(例如,sacubitril)组合禁忌。 不要在切换至去甲肾上腺素/缬沙坦(一种脑啡肽酶抑制剂)后36小时内给予Lotensin HCT(参见警告和注意事项)。
不要将aliskiren与血管紧张素受体阻滞剂,ACE抑制剂(包括Lotensin HCT)共同治疗糖尿病患者。
p>
【INDICATIONS AND USAGE】
Lotensin HCT USP is indicated for the treatment of hypertension.
【DOSAGE AND ADMINISTRATION】
Dose once daily. The dosage may then be increased after 2 to 3 weeks as needed to help achieve blood pressure goals. The maximum recommended dose is 20/25 mg.
Switch Therapy: A patient whose blood pressure is not adequately controlled with benazepril alone or with hydrochlorothiazide alone may be switched to combination therapy with Lotensin HCT. The usual recommended starting dose is 10/12.5 mg once daily to control blood pressure.
Replacement Therapy: The combination may be substituted for the titrated individual components.
【CONTRAINDICATIONS】
Lotensin HCT is contraindicated in patients who are anuric.
Lotensin HCT is also contraindicated in patients who are hypersensitive to benazepril, to any other ACE inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. Hypersensitivity reactions are more likely to occur in patients with a history of allergy or bronchial asthma.
Lotensin HCT is also contraindicated in patients with a history of angioedema with or without previous ACE inhibitor treatment.
Lotensin HCT is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer Lotensin HCT within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see WARNINGS and PRECAUTIONS).
Do not coadminister aliskiren with angiotensin receptor blockers, ACE inhibitors, including Lotensin HCT in patients with diabetes.
---------------------------------------------------------------
详细处方信息以本药内容附件PDF文件(20194119380327.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------